{"product_id":"tirzepatide-5mg","title":"Tirzepatide – 5 mg","description":"\u003cdiv class=\"qvg-desc-rt\"\u003e\n\u003cstyle\u003e\n.qvg-desc-rt{font-family:'Neue Montreal',Helvetica,Arial,sans-serif;color:#6f7f84}\n.qvg-desc-rt p{margin:0 0 15px;font-size:15.5px;font-weight:300;line-height:1.7}\n.qvg-desc-rt strong{color:#233137;font-weight:500}.qvg-desc-rt em{color:#8a969b}\n.qvg-desc-rt sup{line-height:0}.qvg-desc-rt sup a{font-size:11px;font-weight:600;color:#758084;text-decoration:none;padding:0 1px}\n.qvg-desc-rt sup a:hover{color:#233137}\n\u003c\/style\u003e\n\u003cp\u003e\u003cstrong\u003eTirzepatide\u003c\/strong\u003e is a first-in-class \u003cstrong\u003edual GIP and GLP-1 receptor agonist\u003c\/strong\u003e — a single molecule that activates two incretin pathways at once. In peptide research this dual mechanism has drawn intense interest for its effects on appetite signaling, insulin response and \u003cstrong\u003ebody-weight regulation\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eIn the landmark 72-week \u003cstrong\u003eSURMOUNT-1\u003c\/strong\u003e trial, participants on the 15 mg dose recorded a mean \u003cstrong\u003ebody-weight reduction of 20.9%\u003c\/strong\u003e, versus 3.1% on placebo\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e. \u003cstrong\u003e57%\u003c\/strong\u003e of that group lost a fifth or more of their body weight, and \u003cstrong\u003e91%\u003c\/strong\u003e lost at least 5%\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\" target=\"_blank\" rel=\"noopener\"\u003e[1]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eHead-to-head data reinforce the signal: in \u003cstrong\u003eSURPASS-2\u003c\/strong\u003e, tirzepatide produced greater weight loss than semaglutide — up to \u003cstrong\u003e5.5 kg more\u003c\/strong\u003e at the top dose — while lowering HbA1c by \u003cstrong\u003e2.30 points\u003c\/strong\u003e\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2107519\" target=\"_blank\" rel=\"noopener\"\u003e[2]\u003c\/a\u003e\u003c\/sup\u003e. Its dual-receptor design is widely cited as why it outperforms single-pathway GLP-1 agonists\u003csup\u003e\u003ca href=\"https:\/\/doi.org\/10.1002\/oby.23612\" target=\"_blank\" rel=\"noopener\"\u003e[3]\u003c\/a\u003e\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp\u003eSupplied as a \u003cstrong\u003elyophilized powder\u003c\/strong\u003e for reconstitution. \u003cem\u003eFigures above summarize published clinical findings on the tirzepatide molecule and are provided as scientific reference for laboratory research only.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"Qovigen Peptides","offers":[{"title":"Default Title","offer_id":47816108474595,"sku":"T05","price":70.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0777\/1029\/5267\/files\/qovigen-tirzepatide-5-mg.png?v=1784483994","url":"https:\/\/qovigen.com\/products\/tirzepatide-5mg","provider":"Qovigen Peptides","version":"1.0","type":"link"}